England to cover AstraZeneca breast cancer drug under U.S.-U.K. pricing pact

England will now fund AstraZeneca's breast cancer drug following a pricing agreement, partly stemming from the U.S.-U.K. pharmaceutical deal. The move signals tangible policy impact from the bilateral pact, though financial terms and patient eligibility remain undisclosed. This could set a precedent for other drug coverage decisions under the agreement.